Alto Neuroscience (NYSE:ANRO) Price Target Raised to $30.00

Alto Neuroscience (NYSE:ANRO) had its target price lifted by Chardan Capital from $15.00 to $30.00 in a report released on Monday morning, Marketbeat reports. Chardan Capital currently has a buy rating on the stock.

ANRO has been the subject of several other research reports. Jefferies Financial Group increased their price objective on shares of Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. HC Wainwright raised their price target on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, BTIG Research began coverage on Alto Neuroscience in a research report on Monday, November 17th. They set a “buy” rating and a $27.00 target price for the company. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.33.

Alto Neuroscience Trading Up 5.8%

Shares of ANRO opened at $15.96 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $20.91. The company has a 50 day simple moving average of $15.04 and a two-hundred day simple moving average of $8.07. The firm has a market cap of $495.78 million, a P/E ratio of -6.97 and a beta of 2.78.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. On average, equities analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently made changes to their positions in ANRO. SCS Capital Management LLC bought a new position in Alto Neuroscience during the 1st quarter worth about $144,000. Peapod Lane Capital LLC bought a new stake in shares of Alto Neuroscience in the 2nd quarter valued at about $613,000. AlphaCore Capital LLC lifted its position in shares of Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience in the 2nd quarter worth approximately $85,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Alto Neuroscience during the second quarter valued at approximately $33,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.